The M&A-focused Betaville blog sent an alert to its subscribers related to a rumor regarding Janux Therapeutics (JANX), contacts tell The Fly.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics Advances with Promising Study on JANX008 for Solid Tumor Treatment
- Janux Therapeutics Advances Prostate Cancer Study with JANX007
- BTIG biotech analyst holds an analyst/industry conference call
- Janux Therapeutics Announces Departure of Chief Strategy Officer
- Janux Therapeutics initiated with an Overweight at Barclays